ACI Worldwide (NASDAQ:ACIW) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a report issued on Monday. The firm currently has a $59.10 price target on the stock. Zacks‘s price objective would indicate a potential upside of 5.54% from the stock’s previous close. ACI Worldwide Inc (NASDAQ:ACIW) stock performance was 1.03% in last session and finished the day at $18.55. Traded volume was 342,404.00million shares in the last session and the average volume of the stock remained 677.89K shares. The beta of the stock remained 1.04. ACI Worldwide Inc (NASDAQ:ACIW) insider ownership is 1.70%.

Workday Inc (NASDAQ:WDAY) VP James P. Shaughnessy unloaded 8,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $90.98, for a total transaction of $727,840.00. Following the completion of the transaction, the vice president now directly owns 59,709 shares of the company’s stock, valued at approximately $5,432,325. Workday Inc (NYSE:WDAY) rose 1.41 percent to $81.52 Monday on volume of 896,705.00million shares. The intra-day range of the stock was $80.30 to $82.49. Workday Inc (NYSE:WDAY) has a market capitalization of $22.37billion.

On June 26, 2014, Nature’s Sunshine Products, Inc. (NASDAQ:NATR) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd, a company organized in the People’s Republic of China (“Fosun Pharma”) entered into (i) a Stock Purchase Agreement (the “Stock Purchase Agreement”), (ii) a Stockholder Agreement (the “Stockholder Agreement”), and (iii) a Standstill Agreement (the “Standstill Agreement”). On June 26, 2014, the Company, Fosun Industrial Co., Limited (a wholly-owned subsidiary of Fosun Pharma, “Fosun Industrial”) and Nature’s Sunshine Hong Kong Limited (“NSP HK”) entered into a Share Subscription Agreement (the “Subscription Agreement”). Nature’s Sunshine Prod. (NASDAQ:NATR)’s stock on July 14, 2014 reported a decrease of -0.18% to the closing price of $16.31. Its fifty two weeks range is $12.91 -$20.15. The total market capitalization recorded $263.88million. The overall volume in the last trading session was 22,023.00million shares. In its share capital, NATR has 16.19million outstanding shares.

Oppenheimer initiated Ophthotech Corp (NASDAQ:OPHT) with a Outperform and price target of $95 (the note is dated July 7); they expect Ophthotech’s PDGF inhibitor Fovista being developed for wet AMD to succeed in an ongoing Phase 3 program (data 2016), with FDA approval to follow in 2017. Their view is based on solid proof-of-concept from randomized Phase 2 data that showed clear benefits in combination with an approved VEGF inhibitor (standard of care). On Monday, shares of Ophthotech Corp (NASDAQ:OPHT) dropped -1.81% to close the day at $40.60. Company monthly performance is recorded as -8.78%. Ophthotech Corp NASDAQ:OPHT) quarterly revenue growth is 30.71%.